New cocktail therapy aims to stop aggressive prostate cancer in its tracks

NCT ID NCT04194554

Ongoing Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen May 15, 2026 · Last updated May 15, 2026

Summary

This study tests a powerful mix of hormone therapy, a targeted drug (niraparib), and precise radiation in men with high-risk or node-positive prostate cancer. The goal is to find the safest dose and see if this approach can keep PSA levels low for three years. About 100 men are participating across multiple centers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Cornell University

New York, New York, 10065, United States
Mayo Clinic

Rochester, Minnesota, 55901, United States
University Hospitals Seidman Cancer Center

Cleveland, Ohio, 44106, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Texas Southwestern

Dallas, Texas, 75390, United States
Weill Cornell Medicine

New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER